Your browser doesn't support javascript.
loading
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study.
Xu, Jianming; Kato, Ken; Raymond, Eric; Hubner, Richard A; Shu, Yongqian; Pan, Yueyin; Park, Sook Ryun; Ping, Lu; Jiang, Yi; Zhang, Jingdong; Wu, Xiaohong; Yao, Yuanhu; Shen, Lin; Kojima, Takashi; Gotovkin, Evgeny; Ishihara, Ryu; Wyrwicz, Lucjan; Van Cutsem, Eric; Jimenez-Fonseca, Paula; Lin, Chen-Yuan; Wang, Lei; Shi, Jingwen; Li, Liyun; Yoon, Harry H.
Afiliação
  • Xu J; Fifth Medical Center, Chinese PLA General Hospital, Beijing, China.
  • Kato K; National Cancer Center Hospital, Tokyo, Japan.
  • Raymond E; Centre Hospitalier Paris Saint-Joseph, Paris, France.
  • Hubner RA; Department of Medical Oncology, The Christie NHS Foundation Trust/Division of Cancer Sciences, University of Manchester, Manchester, UK.
  • Shu Y; The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
  • Pan Y; Anhui Provincial Hospital, Hefei, China.
  • Park SR; Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
  • Ping L; The First Affiliated Hospital of Xinxiang Medical College, Xinxiang, China.
  • Jiang Y; Cancer Hospital of Shantou University Medical College, Shantou, China.
  • Zhang J; Liaoning Cancer Hospital, Shenyang, China.
  • Wu X; Wuxi Fourth People's Hospital, Wuxi, China.
  • Yao Y; The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
  • Shen L; Beijing Cancer Hospital, Beijing, China.
  • Kojima T; National Cancer Center Hospital East, Chiba, Japan.
  • Gotovkin E; Ivanovo Regional Oncology Dispensary, Ivanovo, Russia.
  • Ishihara R; Osaka International Cancer Institute, Osaka, Japan.
  • Wyrwicz L; Maria Sklodowska-Curie National Cancer Research Institute, Warsaw, Poland.
  • Van Cutsem E; University Hospitals Gasthuisberg, Leuven, and KU Leuven, Leuven, Belgium.
  • Jimenez-Fonseca P; Central University Hospital of Asturias, ISPA, Oviedo, Spain.
  • Lin CY; China Medical University Hospital and China Medical University, Taichung, Taiwan.
  • Wang L; Clinical Development, BeiGene (Beijing), Beijing, China.
  • Shi J; Clinical Biomarker, BeiGene (Beijing), Beijing, China.
  • Li L; Clinical Development, BeiGene (Beijing), Beijing, China.
  • Yoon HH; Department of Oncology, Mayo Clinic, Rochester, MN, USA. Electronic address: yoon.harry@mayo.edu.
Lancet Oncol ; 24(5): 483-495, 2023 05.
Article em En | MEDLINE | ID: mdl-37080222
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Esofágicas / Carcinoma de Células Escamosas do Esôfago Tipo de estudo: Clinical_trials Limite: Adolescent / Adult / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Esofágicas / Carcinoma de Células Escamosas do Esôfago Tipo de estudo: Clinical_trials Limite: Adolescent / Adult / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2023 Tipo de documento: Article